Current - 3 minutes ago

Skip to content

* About

* Team

* Portfolio

* News

* Contact

* Investor Login

Building Companies to

Transform patient outcomes

Investing

in the Future

of Medicine

We create and invest in biotech companies with innovative technologies that are developing life-saving drugs for patients. We invest in both private and public companies, providing a unique longitudinal view of drug development across the industry.

LEARN MORE

30+ Years of Biotech Investing

58 FDA-approved drugs

39 Companies founded since 2010*

*Companies created by MPM BioImpact include portfolio companies where MPM BioImpact was a co-founder or early lead investor from 2010 to today, representing the period that MPM BioImpact’s strategy has been focused on company creation.

We are Company Creators

We built Orna Therapeutics to create a new class of coding RNA medicines that outperforms mRNA.

Orna’s circular RNA technology (oRNA) and best-in-class non-viral delivery are fundamentally changing the landscape of treatment modalities,* starting with replacing cell therapies and improving vaccines.

VISIT THE ORNA SITE

We built Aktis Oncology to realize the transformative potential of alpha radio-pharmaceuticals for patients with solid tumors.

Aktis is pioneering miniprotein actinium-conjugates to deliver breakthrough efficacy and enhanced safety compared to earlier generations of radiopharmaceuticals, while treating a broader set of cancer patients beyond prostate and neuroendocrine tumors.

VISIT THE Aktis SITE

We built ElevateBio to power transformative cell, gene, and RNA therapies.

ElevateBio combines manufacturing, next-generation technologies, and therapeutic development all under one roof.

VISIT THE ELEVATEBIO SITE

We built NextPoint Therapeutics to target a fundamentally new axis in cancer biology.

NextPoint is translating a breakthrough in cancer research into first-in-class, precision therapies for patients in need.

VISIT THE NEXTPOINT SITE

“MPM BioImpact’s commitment to creating transformative medicines for patients has been evident since Orna’s inception. MPM BioImpact saw the potential for circular RNA to solve key challenges with existing cell therapies, and it is their vision that drew me to be part of this exciting effort.”**

Tom Barnes, Ph.D.

Board Member & SCIENTIFIC ADVISORY BOARD Chair

Amit Munshi

CEO

Daniel Anderson, Ph.D.

Co-Founder & Professor, MIT

In the News

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

*Garber, K., "Orna Therapeutics: circular logic," Nature Biotechnology, 05 August 2022, https://doi.org/10.1038/d41587-022-00005-1

**Tom Barnes is not receiving direct compensation for this quote, but has a pecuniary interest that arises from the relationship. Tom receives compensation from certain MPM BioImpact funds.

“Aktis was founded at MPM BioImpact with an ambitious vision to transform the radiopharmaceutical field. The team at MPM BioImpact has lent significant leadership, expertise, and support to enable Aktis to realize this significant patient impact potential.”*

Matthew Roden, Ph.D.

President & CEO

Brian Goodman, Ph.D.

Co-Founder & CBO

In the News

Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

*CEO is not receiving direct compensation for this quote, but is the CEO of a portfolio company that MPM BioImpact invests in and has a pecuniary interest that arises from the relationship. Matthew is also a member of MPM BioImpact’s investment committee and receives compensation from certain MPM BioImpact funds.

“MPM BioImpact is a founding investor and continues to be a key partner as we power advanced therapies through our technology stack and end-to-end manufacturing capabilities.”*

David Hallal

ChaIRman & CEO

Ansbert Gadicke, M.D.

Co-Founder & Board Member

In the News

Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases

*CEO is not receiving direct compensation for this quote, but is the CEO of a portfolio company that MPM BioImpact invests in and has a pecuniary interest that arises from the relationship.

“MPM BioImpact and Dr. Gordon Freeman, pioneer of the PD-1 pathway and NextPoint's scientific co-founder, have a long history of creating transformative cancer therapies together. Building on this partnership, we assembled a world-class team of drug developers to bring the next generation of cancer immunotherapies to patients.”*

Detlev Biniszkiewicz, Ph.D.

CO-FOUNDER & FOUNDING CEO

Gordon Freeman, Ph.D.

CO-FOUNDER & PROFESSOR, DFCI & HARVARD MEDICAL SCHOOL

XingXing Zang, Ph.D.

CO-FOUNDER & PROFESSOR, ALBERT EINSTEIN COLLEGE OF MEDICINE

*CEO is not receiving direct compensation for this quote, but is the CEO of a portfolio company that MPM BioImpact invests in and has a pecuniary interest that arises from the relationship. Detlev is also a member of MPM BioImpact’s investment committee and receives compensation from certain MPM BioImpact funds.

Meet our Team

MPM BioImpact’s investment team consists of professionals who have dedicated their careers to research and drug development, company creation, corporate strategy, and commercialization. Our Entrepreneur Partners provide deep domain expertise as investor-operators and work with our diverse group of scientists and professionals to develop therapies for diseases with high unmet needs. Collectively, we are a team of deeply experienced company creators who help transform scientific discoveries into breakthrough medicines for the patients that need them most.

Learn about our team of experts

Briggs Morrison, M.D.

Entrepreneur Partner

Pankaj Bhargava, M.D.

Entrepreneur Partner

Joseph Bolen, Ph.D.

Entrepreneur Partner

Brendan Furey, J.D.

Compliance

Ansbert Gadicke, M.D.

Investment Team

Kellie Neville

Investor Relations and Marketing

Grey Sieczkiewicz, J.D., Ph.D.

Intellectual Property

Matthew Vander Heiden, M.D., Ph.D.

MEDICAL AND SCIENTIFIC ADVISORY BOARD

David P. Ryan, M.D.

Medical and Scientific Advisory Board

Carolyn Bertozzi, Ph.D.

MEDICAL AND SCIENTIFIC ADVISORY BOARD

Rami Rahal, Ph.D.

Investment Team

Devin Quinlan, Ph.D.

Investment Team

Brian Goodman, Ph.D.

Investment Team

Stephen C. Blacklow, M.D., Ph.D.

Medical and Scientific Advisory Board

Kristen Laguerre, M.B.A.

Finance and Operations

Patrick A. Baeuerle, Ph.D.

MEDICAL AND SCIENTIFIC ADVISORY BOARD

Christian Desmarteaux, M.B.A.

Investor Relations and Marketing

Thomas M. Barnes, Ph.D.

Entrepreneur Partner

John Baclawski

Capital Formation

Luke Evnin, Ph.D.

Investment Team

Andrew M. Scharenberg, M.D.

Entrepreneur Partner

Detlev Biniszkiewicz, Ph.D.

Investment Team

Robert Risoleo, J.D.

Legal

Sam Goldman, Ph.D.

Investment Team

Todd Foley, M.B.A.

Investment Team

Frank Neumann, M.D., Ph.D.

Entrepreneur Partner

Elizabeth Stoner, M.D.

Entrepreneur Partner

Matthew Roden, Ph.D.

Entrepreneur Partner

H. Robert Horvitz, Ph.D.

Medical and Scientific Advisory Board

Wu Jie

Investment Team

Christiana Bardon, M.D., M.B.A.

Investment Team

Christopher Wolf, M.B.A.

Finance

Uciane Scarlett, Ph.D.

Investment Team

Our Portfolio

Portfolio Companies

News and updates

PortfolioInterviews & Articles

October 1, 2024

AstronauTx Appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team

September 30, 2024

Aktis Oncology Announces $175 Million Oversubscribed Series B Financing

July 9, 2024

Aktis Oncology Appoints Akos Czibere, MD, PhD, Chief Medical Officer

May 7, 2024

Ivan Cheung, CEO of NextPoint Therapeutics, Named to TIME Magazine’s Top 100 Most Influential People in Global Health

April 11, 2024

MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner

February 26, 2024

WSJ: Investors Flock Back to Biotech After a Long, Cold Spell – Featuring Chris Bardon

Read All

Building Companies to

Transform

patient outcomes.

Connect with us

LinkedIn Twitter

Contact

info@mpmcapital.com

399 Boylston Street, Suite 1100

Boston, MA 02116

617-425-9200

map

© 2024

MPM BioImpact LLC. All Rights Reserved. Terms of Use | Privacy Policy

BIOIMPACT, MPM, MPM CAPITAL, BIOIMPACT EQUITIES, OIF, ONCOLOGY IMPACT FUND are registered trademarks, and BIOIMPACT logo, MPM BIOIMPACT logo, OIF2 logo, BIOIMPACT CAPITAL MANAGEMENT, BIOIMPACT EQUITIES, BIOIMPACT FUND, MEDICAL IMPACT MANAGEMENT, MIM are trademarks of MPM BioImpact LLC, BioImpact Capital LLC, MPM Capital LLC, and MPM Capital LP.

Top

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue